Vikas S. Sridhar

St. Paul's Hospital
Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Authors' Reply: Could Calcineurin Inhibitor-Driven Sodium-Chloride Cotransporter Activation Explain Blunted Natriuresis with Sodium-Glucose Cotransporter 2 Inhibition in Kidney Transplant Recipients?

Authors' Reply: Could Calcineurin Inhibitor-Driven Sodium-Chloride Cotransporter Activation Explain Blunted Natriuresis with Sodium-Glucose Cotransporter 2 Inhibition in Kidney Transplant Recipients?

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: August 12, 2026

Response to the letter to the editor entitled "Glucodependence in Cardiorenometabolic Disease: Naming the Problem".

Response to the letter to the editor entitled "Glucodependence in Cardiorenometabolic Disease: Naming the Problem".

Journal: Kidney international reports

Published: July 10, 2026

Effect of Sotagliflozin on Kidney Function and Cardio-Kidney-Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD.

Effect of Sotagliflozin on Kidney Function and Cardio-Kidney-Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD.

Journal: Diabetes, obesity & metabolism

Published: July 05, 2026

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: April 03, 2026

Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.

Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.

Journal: Frontiers in cardiovascular medicine

Published: February 11, 2026

Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.

Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.

Journal: Kidney international reports

Published: January 31, 2026

Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.

Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.

Journal: Circulation. Heart failure

Published: January 22, 2026

The allograft survival of kidneys from living donors ≥ 65 years is similar to that of younger living donors in recipients ≥ 35 years.

The allograft survival of kidneys from living donors ≥ 65 years is similar to that of younger living donors in recipients ≥ 35 years.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 28, 2025

The allograft survival of kidneys from living donors aged ≥65 years is similar to that of younger living donors in recipients aged ≥35 years.

The allograft survival of kidneys from living donors aged ≥65 years is similar to that of younger living donors in recipients aged ≥35 years.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 28, 2025

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Journal: Diabetes, obesity & metabolism

Published: December 17, 2025

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 05, 2025

Next-generation therapeutics for diabetic kidney disease.

Next-generation therapeutics for diabetic kidney disease.

Journal: Nature reviews. Nephrology

Published: November 28, 2025

Showing 1-12 of 75

Last Updated: 09/26/2026